1-May-2024
United Therapeutics (UTHR) Gets a Buy from Oppenheimer
TipRanks (Thu, 2-May 8:09 AM ET)
TipRanks (Thu, 2-May 6:32 AM ET)
TipRanks (Thu, 2-May 5:21 AM ET)
TipRanks (Thu, 2-May 5:21 AM ET)
Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
Benzinga (Wed, 1-May 2:35 PM ET)
United Therapeutics GAAP EPS of $6.17 beats by $0.51, revenue of $677.7M beats by $53.51M
Seeking Alpha News (Wed, 1-May 6:37 AM ET)
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
Business Wire (Wed, 1-May 6:30 AM ET)
United Therapeutics Q1 2024 Earnings Preview
Seeking Alpha News (Tue, 30-Apr 11:53 AM ET)
Notable earnings before Wednesday's open
Seeking Alpha News (Tue, 30-Apr 10:46 AM ET)
United Therapeutics Announces World's First Successful Xenothymokidney Transplant
Business Wire (Wed, 24-Apr 9:00 AM ET)
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
United Therapeutics trades on the NASDAQ stock market under the symbol UTHR.
As of May 1, 2024, UTHR stock price climbed to $255.14 with 1,264,351 million shares trading.
UTHR has a beta of 0.52, meaning it tends to be less sensitive to market movements. UTHR has a correlation of 0.06 to the broad based SPY ETF.
UTHR has a market cap of $11.32 billion. This is considered a Large Cap stock.
Last quarter United Therapeutics reported $615 million in Revenue and $4.36 earnings per share. This beat revenue expectation by $39 million and exceeded earnings estimates by $.17.
In the last 3 years, UTHR stock traded as high as $283.09 and as low as $158.38.
The top ETF exchange traded funds that UTHR belongs to (by Net Assets): IJH, VTI, VB, VBR, VXF.
UTHR stock has underperformed the market in the last year with a return of +9.9%, while SPY returned +22.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in UTHR shares. However, UTHR has outperformed the market in the last 3 month and 2 week periods, returning +18.1% and +8.4%, while SPY returned +2.6% and 0.0%, respectively. This indicates UTHR has been having a stronger performance recently.
UTHR support price is $230.62 and resistance is $238.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UTHR stock will trade within this expected range on the day.